Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1171-1172

  Cousin, S ^a,b   Toulmonde, M ^a,b   Kind, M ^c   Cazeau, A L ^d   Bechade, D ^b   Coindre, J M ^e   Italiano, A ^a,b  

^a Early Phase Trials Unit   (France)

^b University of Medicine   (France)

^c Departments of Radiology   (France)

^d centre universitaire de Bordeaux   (France)

^e INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PEMBROLIZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMAGE GUIDED BIOPSY; LUNG METASTASIS; LUNG SARCOIDOSIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; ULTRASOUND; UTERUS SARCOMA; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FEMALE; HUMANS; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SARCOIDOSIS, PULMONARY;

EID: 84974817532     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw125     Document Type: Letter

References (5)

1. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. NEJM 2015; 372(26): 2521-2532.
2. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. NEJM 2015; 372(21): 2018-2028.
3. Wilgenhof S, Morlion V, Seghers AC et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res 2012; 32(4): 1355-1359.
4. Vogel WV, Guislain A, Kvistborg P et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 2012; 30 (2): e7-e10.
5. Berthod G, Lazor R, Letovanec I et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012; 30(17): e156-e159.